Cyclins and their catalytic partners, the cyclin-dependent kinases (CDKs), control the transition between different phases of the cell cycle. CDK/cyclin activity is regulated by CDK inhibitors (CKIs), currently comprising the CDK-interacting protein/kinase inhibitory protein (CIP/KIP) family and the inhibitor of kinase (INK) family. Recent studies have identified a third group of CKIs, called ribosomal protein-inhibiting CDKs (RPICs). RPICs were discovered in the context of cellular senescence, a stable cell cycle arrest with tumor-suppressing abilities. RPICs accumulate in the nonribosomal fraction of senescent cells due to a decrease in rRNA biogenesis. Accordingly, RPICs are often downregulated in human cancers together with other ribosomal proteins, the tumor-suppressor functions of which are still under study. In this review, we discuss unique therapies that have been developed to target CDK activity in the context of cancer treatment or senescence-associated pathologies, providing novel tools for precision medicine. The cell cycle is a complex process that is controlled by multiple regulatory pathways that also integrate extracellular signals to govern cell growth and division.Ribosomal proteins are key regulators of the cell cycle. Recent research studies confirmed the existence of a third class of cyclin-dependent kinase (CDK) inhibitors, besides CDK-interacting protein/kinase inhibitory protein (CIP/KIP) and inhibitor of kinase (INK) families, called ribosomal protein inhibiting CDKs (RPICs).The new cell cycle regulators constitute valuable targets for precision medicine, through the identification of peptides or small molecules mimicking their CDK inhibitor activities, opening novel avenues for the treatment of cancer and aging-related diseases.